Literature DB >> 8681574

Surfactant content in children with inflammatory lung disease.

A M LeVine1, A Lotze, S Stanley, C Stroud, R O'Donnell, J Whitsett, M M Pollack.   

Abstract

OBJECTIVE: To determine surfactant profiles of tracheal secretions in mechanically ventilated children with respiratory failure secondary to bacterial pneumonia, viral pneumonitis, adult respiratory distress syndrome (ARDS), and cardiopulmonary bypass.
DESIGN: Prospective, cohort study.
SETTING: Tertiary, multidisciplinary, pediatric intensive care unit. PATIENTS: One hundred twenty pediatric patients with respiratory failure requiring mechanical ventilation.
INTERVENTIONS: Routine tracheal aspirates were collected from children with bacterial pneumonia, viral pneumonitis, ARDS, postcardiopulmonary bypass, and a postsurgical control group. Samples were obtained on days 1, 2, 3, after every week of intubation and on the day of extubation.
MEASUREMENTS AND MAIN RESULTS: The tracheal aspirates were analyzed by high-performance liquid chromatography for lecithin/sphingomyelin rations and by enzyme-linked immunosorbent assay for surfactant proteins A and B. Lung compliance and the oxygenation index were measured on each day of sample collection. On day 1, patients with bacterial pneumonia, viral pneumonitis, and ARDS had decreased lecithin/sphingomyelin ration (p < .001), and those patients with bacterial pneumonia and viral pneumonitis had decreased surfactant protein A/protein concentration (p < .001). The lecithin/sphingomyelin ratios and surfactant protein A/protein concentration were significantly different among the groups (p < .001), with the bacterial pneumonia and viral pneumonitis groups having higher lecithin/sphingomyelin ratios and increased surfactant protein concentrations before extubation. Pulmonary compliance was lower and the oxygenation index was higher than controls (p < .001) in patients with bacterial pneumonia, viral pneumonitis, and ARDS. Pulmonary compliance was correlated weakly with lecithin/sphingomyelin ratio (r2 = .11, p < .001) and surfactant protein A/protein concentration (r2 = .03, p < .05). Surfactant protein B was similar in the diagnostic groups. Surfactant content in tracheal secretions from cardiopulmonary bypass patients was equivalent to controls.
CONCLUSION: Abnormal tracheal aspirate surfactant phospholipids and surfactant protein A were noted in children with bacterial pneumonia, viral pneumonitis, and ARDS, but not in children on cardiopulmonary bypass.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8681574     DOI: 10.1097/00003246-199606000-00029

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  24 in total

1.  Lung infections and innate host defense.

Authors:  Ma Valdivia-Arenas; A Amer; Ln Henning; Md Wewers; Ls Schlesinger
Journal:  Drug Discov Today Dis Mech       Date:  2007

2.  Hemolytic phospholipase C inhibition protects lung function during Pseudomonas aeruginosa infection.

Authors:  Matthew J Wargo; Maegan J Gross; Sathish Rajamani; Jenna L Allard; Lennart K A Lundblad; Gilman B Allen; Michael L Vasil; Laurie W Leclair; Deborah A Hogan
Journal:  Am J Respir Crit Care Med       Date:  2011-05-11       Impact factor: 21.405

3.  The Pseudomonas aeruginosa flagellum confers resistance to pulmonary surfactant protein-A by impacting the production of exoproteases through quorum-sensing.

Authors:  Zhizhou Kuang; Yonghua Hao; Sunghei Hwang; Shiping Zhang; Eunice Kim; Henry T Akinbi; Michael J Schurr; Randall T Irvin; Daniel J Hassett; Gee W Lau
Journal:  Mol Microbiol       Date:  2011-01-06       Impact factor: 3.501

4.  Increased surfactant protein D fails to improve bacterial clearance and inflammation in serpinB1-/- mice.

Authors:  J Michael Stolley; Dapeng Gong; Kalamo Farley; Picheng Zhao; Jessica Cooley; Erika C Crouch; Charaf Benarafa; Eileen Remold-O'Donnell
Journal:  Am J Respir Cell Mol Biol       Date:  2012-09-28       Impact factor: 6.914

Review 5.  Surfactant therapy for acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; D Willson; R H Notter
Journal:  Crit Care Clin       Date:  2011-07       Impact factor: 3.598

6.  Surfactant protein-A enhances respiratory syncytial virus clearance in vivo.

Authors:  A M LeVine; J Gwozdz; J Stark; M Bruno; J Whitsett; T Korfhagen
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

7.  Topical interleukin-8 antibody attracts leukocytes in a piglet lavage model.

Authors:  Tobias Ankermann; Tina Wiemann; Anja Reisner; Marzenna Orlowska-Volk; Heike Köhler; Martin F Krause
Journal:  Intensive Care Med       Date:  2004-10-20       Impact factor: 17.440

8.  Surfactant treatment for acute respiratory distress syndrome.

Authors:  J López-Herce; N de Lucas; A Carrillo; A Bustinza; R Moral
Journal:  Arch Dis Child       Date:  1999-03       Impact factor: 3.791

9.  Interleukin-4 enhances pulmonary clearance of Pseudomonas aeruginosa.

Authors:  S Jain-Vora; A M LeVine; Z Chroneos; G F Ross; W M Hull; J A Whitsett
Journal:  Infect Immun       Date:  1998-09       Impact factor: 3.441

Review 10.  Surfactant for pediatric acute lung injury.

Authors:  Douglas F Willson; Patricia R Chess; Robert H Notter
Journal:  Pediatr Clin North Am       Date:  2008-06       Impact factor: 3.278

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.